Erratum: Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum.
单位:[1]Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China.华中科技大学同济医学院附属同济医院外科学系泌尿外科[2]Institute of Urology of Hubei Province, Wuhan, China.[3]Department of Urinary Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.[4]Department of Urology, The First Affiliated Hospital of Xiamen University, Xiamen, China.[5]Department of Urology, The People's Hospital of Shenzhen City, Shenzhen, China.深圳市人民医院深圳市康宁医院深圳医学信息中心[6]Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, USA.
第一作者单位:[1]Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China.[2]Institute of Urology of Hubei Province, Wuhan, China.
推荐引用方式(GB/T 7714):
Yan Libin,Ding Beichen,Liu Haoran,et al.Erratum: Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum.[J].Theranostics.2022,12(1):419-420.doi:10.7150/thno.68810.
APA:
Yan Libin,Ding Beichen,Liu Haoran,Zhang Yangjun,Zeng Jin...&Xu Hua.(2022).Erratum: Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum..Theranostics,12,(1)
MLA:
Yan Libin,et al."Erratum: Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum.".Theranostics 12..1(2022):419-420